|
|||||
|
|
First evidence: rivaroxaban and apixaban reduce thrombin-dependent platelet aggregation |
|
| Authors: | Juraj Sokol Frantisek Nehaj Jela Ivankova Michal Mokan Marian Mokan |
| Affiliation: | 1.Department of Haematology and Transfusion Medicine, National Centre of Haemostasis and Thrombosis, Jessenius Faculty of Medicine in Martin,Comenius University in Bratislava,Martin,Slovakia;2.First Department of Internal Medicine, Jessenius Faculty of Medicine in Martin,Comenius University in Bratislava,Martin,Slovakia |
| Abstract: | Rivaroxaban and apixaban are direct oral anticoagulants whose target specificity is to activate factor X (FXa). It is still not fully understood how xabans impact platelet function. This single-center observational study aimed to assess in vitro platelet function in patients with atrial fibrillation receiving rivaroxaban or apixaban. It examined quantification of platelet aggregation assessed by light transmission aggregometry in thirty-four patients treated with apixaban or rivaroxaban. The thrombin-induced platelet aggregation was significantly lower 2 h after taking selected xabans compared to baseline value (69.55?±?32.15% vs. 44.79?±?34.97.9%; p? |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |